A common long-term worry in the GLP-1 community goes like this: if you keep stimulating the GLP-1 receptor week after week, won't it eventually "burn out"? People mean a few different things by that. The drug might stop working, you might need endless dose increases, or your body's own appetite system might end up permanently damaged and worse off than before you started.
It's a fair question, and it has some basis in biology. The long-term evidence, though, is much more reassuring than the word "burnout" suggests.
Where the idea comes from
The GLP-1 receptor is a G-protein-coupled receptor, and receptors in that family can desensitize, dialing down their response when they're stimulated continuously. That's a real cellular phenomenon studied in pharmacology.
One GLP-1 effect does fade this way. The slowing of stomach emptying wears off quickly with continuous exposure, a process called tachyphylaxis. In healthy volunteers given a steady GLP-1 infusion, the hormone slowed stomach emptying much more after the first meal than after a second meal four hours later (Nauck et al., Diabetes, 2011, DOI (external link)).
A fading effect on the stomach is a long way from the whole treatment quitting. Whether a drug keeps working over months and years is a question for long-term clinical data.
What the long-term trials show
In the STEP 5 trial, adults taking semaglutide for two years lost about 15% of their body weight (−15.2%) and kept it off, versus 2.6% with placebo, with the loss sustained across the full 104 weeks (Garvey et al., Nat Med, 2022, DOI (external link)). The effect didn't erode as it would if the receptors were wearing out. With continued treatment, the medication kept working.
Then why do I plateau?
Weight loss slows and stops for almost everyone, and the usual reason is a new equilibrium. As you get smaller, your body needs fewer calories, so the intake that once produced a deficit eventually matches your new energy needs. The medication is still holding your appetite down, now at a lower body weight. Our guide on what to realistically expect on a GLP-1 covers the plateau in detail, and how the medications work explains the receptor side.
Dose also matters. Some people get more effect after a dose increase, which is part of why titration exists. That's normal dose-response managed by a clinician, not permanent tolerance.
Does long-term use damage your own GLP-1 system?
This worries people most, and there's no good evidence that these medications permanently exhaust or break your natural appetite regulation.
What happens when people stop points the other way. In the STEP 1 extension, people who stopped semaglutide regained about two-thirds of the weight they had lost within a year (Wilding et al., Diabetes, Obesity & Metabolism, 2022, DOI (external link)). That's frustrating. The study measured weight, not appetite hormones, but the pattern is consistent with your own system picking back up once the medication is gone: it was being supplemented, not destroyed. It's also why obesity is treated as a chronic condition that needs ongoing management.
What about long-term safety?
The largest long-term safety data come from trials lasting several years. In SELECT, 17,604 people with heart disease and overweight or obesity took semaglutide 2.4 mg or placebo, with a mean follow-up of 39.8 months. Adverse events led 16.6% of people on semaglutide to stop the drug, versus 8.2% on placebo (Lincoff et al., New England Journal of Medicine, 2023, DOI (external link)). Most side effects are the familiar gastrointestinal ones, but the label lists others to know about: a boxed warning about thyroid C-cell tumors (seen in rodents), acute pancreatitis, gallbladder disease, kidney injury from dehydration, low blood sugar, allergic reactions, a faster heart rate, and diabetic eye complications in people with type 2 diabetes (Wegovy prescribing information (external link), revised June 2026).
On the scale of a lifetime these are still new medications, so long-term use should be supervised. Regular check-ins let your prescriber monitor how it's going and adjust, including tapering to a lower maintenance dose instead of staying at your highest dose indefinitely.
Study findings above are attributed to their authors and were located via PubMed.
This is general education, not medical advice. Questions about long-term use and your specific situation are worth raising with your prescriber.